AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2041-4889

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells ; volume:10 ; number:5 ; day:1 ; month:5 ; year:2019 ; pages:1-12 ; date:5.2019
Cell death & disease ; 10, Heft 5 (1.5.2019), 1-12, 5.2019

Classification: Medizin, Gesundheit

Creator: Kim, Donghwa
Bach, Duc-Hiep
Fan, Yan-Hua
Luu, Thi-Thu-Trang
Hong, Ji-Young
Park, Hyen Joo
Lee, Sang Kook

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41419-019-1601-6

URN: urn:nbn:de:101:1-2019052419575869932786

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:52 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Kim, Donghwa
Bach, Duc-Hiep
Fan, Yan-Hua
Luu, Thi-Thu-Trang
Hong, Ji-Young
Park, Hyen Joo
Lee, Sang Kook
SpringerLink (Online service)

Other Objects (12)

Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer

Correction: The HDAC inhibitor, MPT0E028, enhances erlotinib induced cell death in EGFR-TKI-resistant NSCLC cells

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Graffiti | Streetart

TKi | TKi

Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer

Correction: The HDAC inhibitor, MPT0E028, enhances erlotinib induced cell death in EGFR-TKI-resistant NSCLC cells

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Graffiti | Streetart

TKi | TKi

Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer

Correction: The HDAC inhibitor, MPT0E028, enhances erlotinib induced cell death in EGFR-TKI-resistant NSCLC cells

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Graffiti | Streetart

TKi | TKi

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer

Correction: The HDAC inhibitor, MPT0E028, enhances erlotinib induced cell death in EGFR-TKI-resistant NSCLC cells

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

TKi | TKi

Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer

Correction: The HDAC inhibitor, MPT0E028, enhances erlotinib induced cell death in EGFR-TKI-resistant NSCLC cells

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

TKi | TKi

Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer

Correction: The HDAC inhibitor, MPT0E028, enhances erlotinib induced cell death in EGFR-TKI-resistant NSCLC cells

EGFR T790M mutation as a novel target for immunotherapy against EGFR-TKI-resistant non-small cell lung cancer

CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant non-small-cell lung cancer

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer

The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

TKi | TKi

Related objects

Reset password